Viatris Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?

Viatris Inc. vs. Mesoblast Limited: A Tale of SG&A Management

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Viatris Inc. and Mesoblast Limited have showcased contrasting strategies in handling these costs. From 2014 to 2023, Viatris Inc. consistently reported higher SG&A expenses, peaking at approximately $4.65 billion in 2023. In contrast, Mesoblast Limited maintained a more conservative approach, with expenses averaging around $47 million annually.

Interestingly, while Viatris Inc.'s SG&A expenses surged by over 200% from 2014 to 2023, Mesoblast Limited demonstrated a more stable trend, with a notable dip in 2024. This suggests a strategic pivot or operational efficiency. The absence of data for Viatris Inc. in 2024 leaves room for speculation on future trends. As investors and analysts scrutinize these figures, the question remains: which company will leverage its SG&A strategy for sustainable growth?